Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIF001 in Healthy Subjects and Patients With Epilepsy
NCT07051629Phase 1Recruiting
- Sponsor
- Suninflam
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in epilepsy comparing SIF001 10-80mg/kg IV with Placebo (2 arms). Primary endpoint: Treatment-related adverse events at Day 43. Started Jun 2025; status: recruiting.
02
Drugs
SIF001
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT07051629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07051629.